Published in Medical Device Business Week, May 28th, 2008
"In vitro cell binding assays demonstrated selective binding [Tc-99m]2 to human umbilical vein endothelial ( HUVE) cells, with inhibition of binding to 37.3% of control levels by 10 mc M of cold authentic compounds. In addition, [Tc-99m]2...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Device Business Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.